Survival and Prognostic Analysis after Pulmonary Metastasectomy for Head and Neck Cancer

Abstract

Background There is no consensus on the value of pulmonary metastasectomy (PM) for head and neck cancer (HNC). The aim of our single-institution study was to evaluate outcomes and to examine factors influencing 5-year survival of patients undergoing resections for HNC lung metastases.

Methods All HNC patients undergoing curative-intent PM between January 2008 and December 2018 were retrospectively analyzed. The impact of factors related to primary tumor, metastases, and associated therapy on patient survival was evaluated using the univariable Cox proportional hazard model. Cutoff values of continuous variables were determined by a receiver operating characteristic analysis.

Results In total, 44 patients (32 males and 12 females, with a median age of 65 years) underwent PM for metastatic HNC. There was one perioperative death, and major complications occurred in 2 (4.5%) patients. The median interval between the treatment of primary tumor and PM was 19.4 months (range: 0–151 months). Median size of the largest resected pulmonary lesion was 1.3 cm (range: 0.3–6.9 cm). Mean follow-up was 21 months (range: 0–123 months), and 5-year overall survival (OS) rate after the first PM was 41%. Resection was complete (R0) in all patients. Larger size of pulmonary metastasis (≥1.4 cm; hazard ratio: 4.49; 95% confidence interval: 1.79–11.27) was a significantly negative prognostic factor.

Conclusion Despite the lack of randomized controlled trials, PM for HNC is a reasonable therapeutic option with favorable survival in a selected population. In patients with larger pulmonary lesions, shorter OS after PM is to be expected.

Keywords

head and neck cancer - lung metastases - survival - pulmonary metastasectomy

Publikationsverlauf

Eingereicht: 04. März 2020

Angenommen: 01. Mai 2020

Artikel online veröffentlicht:
19. Juni 2020

• References

• 1 Duprez F, Berwouts D, De Neve W. et al. Distant metastases in head and neck cancer. Head Neck 2017; 39 (09) 1733-1743
• 2 Vermorken JB, Mesia R, Rivera F. et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359 (11) 1116-1127
• 3 Miyazaki T, Hasegawa Y, Hanai N. et al. Survival impact of pulmonary metastasectomy for patients with head and neck cancer. Head Neck 2013; 35 (12) 1745-1751
• 4 Young ER, Diakos E, Khalid-Raja M, Mehanna H. Resection of subsequent pulmonary metastases from treated head and neck squamous cell carcinoma: systematic review and meta-analysis. Clin Otolaryngol 2015; 40 (03) 208-218
• 5 Dudek W, Schreiner W, Hohenberger W, Klein P, Sirbu H. Forty-two years' experience with pulmonary resections of metastases from colorectal cancer. Thorac Cardiovasc Surg 2017; 65 (07) 560-566
• 6 Dudek W, Schreiner W, Mykoliuk I, Higaze M, Sirbu H. Pulmonary metastasectomy for sarcoma-survival and prognostic analysis. J Thorac Dis 2019; 11 (08) 3369-3376
• 7 Wedman J, Balm AJ, Hart AA. et al. Value of resection of pulmonary metastases in head and neck cancer patients. Head Neck 1996; 18 (04) 311-316
• 8 Dennington ML, Carter DR, Meyers AD. Distant metastases in head and neck epidermoid carcinoma. Laryngoscope 1980; 90 (02) 196-201
• 9 Liu D, Labow DM, Dang N. et al. Pulmonary metastasectomy for head and neck cancers. Ann Surg Oncol 1999; 6 (06) 572-578
• 10 Pfister DG, Spencer S, Adelstein D. et al. Head and neck cancers: very advanced head and neck cancer. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology, Version 1. https://www.nccn.org/professionals/physician_gls/default.aspx#head-and-neck . Accessed March 4, 2020
• 11 AlShammari A, Almasri T, Sarraj J. et al. Pulmonary metastasis of head and neck cancer: surgical removal outcomes from a tertiary care center. Indian J Thorac Cardiovasc Surg 2020; 36: 199-206
• 12 Oki T, Hishida T, Yoshida J. et al. Survival and prognostic factors after pulmonary metastasectomy of head and neck cancer: what are the clinically informative prognostic indicators?. Eur J Cardiothorac Surg 2019; 55 (05) 942-947
• 13 Nakajima Y, Iijima Y, Kinoshita H. et al. Surgical treatment for pulmonary metastasis of head and neck cancer: study of 58 cases. Ann Thorac Cardiovasc Surg 2017; 23 (04) 169-174
• 14 Atabek U, Mohit-Tabatabai MA, Raina S, Rush Jr BF, Dasmahapatra KS. Lung cancer in patients with head and neck cancer. Incidence and long-term survival. Am J Surg 1987; 154 (04) 434-438
• 15 Geurts TW, Nederlof P, van den Brekel MW. et al. Pulmonary squamous cell carcinoma: metastasis or second primary?. Clin Cancer Res 2005; 11: 6608-6614
• 16 Geurts TW, Balm AJ, van Velthuysen ML. et al. Survival after surgical resection of pulmonary metastases and second primary squamous cell lung carcinomas in head and neck cancer. Head Neck 2009; 31 (02) 220-226
• 17 Bishop JA, Ogawa T, Chang X. et al. HPV analysis in distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma. Am J Surg Pathol 2012; 36 (01) 142-148
• 18 Shiono S, Kawamura M, Sato T. et al; Metastatic Lung Tumor Study Group of Japan. Pulmonary metastasectomy for pulmonary metastases of head and neck squamous cell carcinomas. Ann Thorac Surg 2009; 88 (03) 856-860
• 19 Mochizuki T, Okumura S, Ishii G. et al. Surgical resection for oral tongue cancer pulmonary metastases. Interact Cardiovasc Thorac Surg 2010; 11 (01) 56-59
• 20 Nibu K, Nakagawa K, Kamata S. et al. Surgical treatment for pulmonary metastases of squamous cell carcinoma of the head and neck. Am J Otolaryngol 1997; 18 (06) 391-395
• 21 Yotsukura M, Kinoshita T, Kohno M. et al. Survival predictors after resection of lung metastases of head or neck cancers. Thorac Cancer 2015; 6 (05) 579-583
• 22 Treasure T, Farewell V, Macbeth F. et al; PulMiCC Trial Group. Pulmonary Metastasectomy versus Continued Active Monitoring in Colorectal Cancer (PulMiCC): a multicentre randomised clinical trial. Trials 2019; 20 (01) 718